False nonresponders to anti-calcitonin gene-related peptide monoclonal antibodies: A real-world analysis beyond migraine frequency reduction.

ABSTRACT:

Objectives/background

Reimbursement criteria for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) typically rely on predefined reductions in monthly migraine days (MMD). However, this approach may fail to capture the full spectrum of treatment benefits, potentially leading to premature discontinuation in patients experiencing meaningful improvements in other parameters.

Methods

This was a retrospective observational cohort study of prospectively collected data from a multicenter headache unit (Hospital Universitari de Bellvitge and Hospital de Viladecans, Barcelona, Spain) between December 2019 and September 2024. We included patients with migraine who initiated anti-CGRP MAbs and who, at 6 months, would not meet institutional reimbursement criteria f

SUBMITTER: Munoz-Vendrell A 

PROVIDER: S-EPMC12849535 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature